Intensive Lowering of LDL Cholesterol Levels with Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial

FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with stable atherosclerosis who were taking statins. This analysis focused on the effect of evolocumab in patients with or without an autoimmune or inflammatory disease, defined as any autoimmune or chronic inflammatory condition.